10 Years Treating Bifurcations: Have We Made Progress?

Bifurcations have been, are and will be challenging. However, we have to admit we have gained experience and have more tools than pioneer interventionists and many of the early experts who have made history. 

10 años tratando bifurcaciones

This study assessed the ten-year trends in coronary bifurcation percutaneous coronary intervention (PCI) looking at patient and lesion characteristics, devices used, strategy and stent optimization techniques. 

It included over 5,000 patients receiving bifurcation PCI between 2004 and 2015. Primary end point at 2 years was target vessel failure (combination of cardiac death, MI and any revascularization).

During the 10-year study period patient and lesion grew in complexity: multivessel, diabetes, chronic kidney failure and left main disease rates increased gradually (p<0.001 for all).

On the other hand, the risk of target vessel failure saw a steady drop, from 12.3% in 2004 to 6.9% in 2015 (to nearly half).


Read also: Device Evolution Also Impacts on Valve in Valve.


The two variables driving outcome improvement were mainly second-generation drug eluting stents (not surprisingly), and the significant dip of true bifurcations (Medina 1,1,1 y 0,1,1).

Conclusion

During the last decade of bifurcation PCI, patient and lesion characteristics, devices, techniques and ultimately population prognosis have significantly changed. Although over time patients and lesions have become more complex, outcomes have improved thanks to device development, technique optimization and more appropriate strategies. 

JAHA-121-021632

Original Title: Ten-Year Trends in Coronary Bifurcation Percutaneous Coronary Intervention: Prognostic Effects of Patient and Lesion Characteristics, Devices, and Techniques.

Reference: Joo Myung Lee et al. J Am Heart Assoc. 2021 Sep 21;10(18):e021632. doi: 10.1161/JAHA.121.021632.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...